Objectives: Inflammation in the setting of acute pancreatitis (AP) is partially driven by pathogen recognition receptors that recognize damageassociated molecular patterns. Interleukin (IL)-8 is a chemotactic factor produced by pathogen recognition receptor-expressing cells. A singlenucleotide polymorphism in IL8 promoter region (−251 A/T) has been implicated in inflammatory diseases. We examined whether this IL8 polymorphism confers susceptibility to AP.
A cute pancreatitis (AP) is a common and potentially lifethreatening condition resulting from pancreatic parenchymal inflammation. In the United States, AP is the leading cause of gastrointestinal related hospital admissions. 1 The high incidence of AP underlies the economic burden in terms of high cost of care and lost productivity. Most cases of AP are mild, characterized histologically by glandular edema with neutrophil infiltrates, and are associated with rapid clinical recovery. A significant fraction of patients, however, suffers a severe course associated with systemic inflammatory response and organ failure with high morbidity and mortality. 2 Acute pancreatitis is instigated by pancreatic injury and architectural distortion, resulting in the release of sequestered zymogens into interstitial spaces. The injury induces a poorly understood inflammatory cascade with endothelial injury, vascular leak, and bacterial translocation. 3 This can manifest with severe complications including pancreatic necrosis, systemic inflammation, and organ failure with their attendant mortality.
Immune cells are critical components of inflammation in AP. Innate cells, such as neutrophils, express pathogen recognition receptors (PRRs) that recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Upon ligand binding, PRRs activate cascades culminating in the production of prototypical inflammatory cytokines such as interleukin (IL)-1β, IL-6, and TNFα. [4] [5] [6] Bacterial translocation and parenchymal injury in AP result in exposure of both PAMPs and DAMPs, resulting in a perpetual cycle of injury.
In this regard, interleukin-8 (IL8) is a powerful chemotactic factor for neutrophils and is produced by PRR-expressing cells. Consistent with the role of IL8 in inflammation, a functional singlenucleotide polymorphism (SNP) (rs4073) in the IL8 promoter (−251 A/T) has been implicated in inflammatory conditions including cancer, periodontitis, and Helicobacter pylori gastritis. [7] [8] [9] The burden of AP is well-known; however, the mechanisms that perpetuate AP are incompletely understood. There are, to-date, a very limited number of studies that have reproducible identified risk alleles for AP. The published studies have suffered from low patient numbers, are typically retrospective, and generally do not contain detailed data regarding clinical outcomes. Therefore, the limited available data have been mixed and poorly reproducible.
The cohort of patients with AP at the University of Pittsburgh Medical Center (UPMC) is well characterized clinically and has been extensively published. This cohort is ongoing and is prospectively enrolled with associated serum samples to obtain biochemical data. Given the paucity of genetic studies in AP, we used this clinically well characterized cohort to perform a candidate gene study to determine whether this SNP confers susceptibility to, or modulate the severity of, AP. We additionally assessed the gene-environment interactions by examining the role of obesity, a known important risk factor for severe pancreatitis, in risk and severity in the setting of AP in the setting of IL8 polymorphisms.
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MATERIALS AND METHODS
Subjects
Prospectively recruited patients and control subjects provided written informed consent before study enrollment. The institutional review board of the University of Pittsburgh approved this study. The diagnosis of AP was based on the presence of at least 2 of 3 characteristic clinical, biochemical, and/or radiographic criteria and was in accordance with the standard clinical definition. Inclusion criteria were as follows: (1) any patient admitted to the UPMC with the above criteria older than 18 years and (2) ability to give informed written consent and admitted within 7 days of onset of pain. Patients were excluded if (1) they presented greater than 7 days from the onset of pain, (2) active malignancy, and (3) inability to provide written informed consent. We restricted included subjects to the 7-day cutoff because we wanted to capture early rather than the late phase of AP. At the end of their hospitalization, patients were classified clinically as having either mild acute pancreatitis (MAP), moderate acute pancreatitis (MoAP), or severe acute pancreatitis (SAP). The definitions were based in the Revised Atlanta Classification, 12 with SAP defined as development of persistent organ failure (OF). Organ failure was defined by the modified Marshall score involving the cardiovascular, respiratory, and/or renal organ systems. Patients were considered to have persistent single OF if they met 1 of the latter criteria for 48 hours or more, and multi-OF if they met 2 or more criteria. Control subjects were recruited from the hospital and clinics at UPMC and included spouses and unrelated healthy subjects. Control subjects were excluded if they were (1) younger than 18 years old, (2) could not provide informed written consent, and had either (3) active malignancy, (4) infection, or (5) autoimmune conditions.
DNA Isolation and Genotyping Protocols
Whole blood was obtained at enrollment. Samples were placed in EDTA tubes and underwent diffusion centrifugation to isolate lymphocytes. Cells were isolated from the appropriate layer of the gradient centrifugation and then lysed for DNA extraction. DNA was isolated and processed using the FlexiGene DNA kit (Qiagen, Valencia, Calif ) per kit instructions. The DNA was quantitated using a spectrophotometer (Nanodrop, Thermo Scientific, Waltham, Mass). The amount of DNA varied but was generally between 12 and 15 ng and was within range (1-20 ng) specified by the SNP genotyping assay kit. Primer pair was designed to amplify a 275 bp region of IL8 promoter containing −251 A/T polymorphism (TTATCTAGAAATAAAAAAGCATACA[A/T] TTGATA ATTCACCAAAT -TGTGGAGCTTATCTAGAAATAAAAAA). Polymerase chain reaction amplification was performed per SNP Genotyping Assay kit instructions (Life Technologies, Grand Island, NY). The samples were then processed using the Taqman assay (primer C_11748116_10) (Life Technologies). Fluorescence was measured using a commercially available polymerase chain reaction system (AB 7900HT, Applied Biosystems, Life Technologies).
Statistical Analysis
Genotype frequencies were calculated and tested for adherence to Hardy-Weinberg equilibrium using a χ 2 test with 1 degree of freedom. Comparison between genotype frequencies was made using Armitage trend tests. The χ 2 test was applied to compare genotype frequencies and determine odds ratios (ORs) and 95% confidence intervals (CIs) between groups. The α of 0.05 was considered statistically significant (P < 0.05). Continuous variables were analyzed using Student's t-test or analysis of variance (in instances where there were more than 2 groups to be analyzed). All statistical analyses were performed using prism (GraphPad, San Diego, Calif ).
RESULTS
Patient Demographics and Outcomes
Three hundred fifty-seven patients were recruited between 2003 and 2014 (mean age, 52 years; 50% females; mean body mass index [BMI] , 29 kg/m 2 ). In addition, blood from 347 healthy control subjects without a history of AP was also analyzed (mean age, 54 years; 61% females; mean BMI, 28 kg/m 2 ). When comparing patients and controls, age and BMI were similar; however, controls had more females (P < 0.0001).
The majority of patients had MAP (n = 192, 54%), followed by MoAP (n = 77, 21.5%) and SAP (n = 88, 24.5%) ( Table 1) . Patients with SAP were more likely to be male (P < 0.0001) and have a higher BMI (P = 0.002), which is consistent with prior publications. Biliary pancreatitis was the most common etiology among all patients (40%), followed by idiopathic (19%) ( Table 1) . Patients with SAP were enriched for biliary or hypertriglycerideinduced AP (P < 0.003), whereas MAP was associated with idiopathic and post-endoscopic retrograde cholangiopancreatography AP ( Table 1) .
As expected, patients with SAP had worse outcome compared with those with MoAP and MAP ( Table 2 ). Length of stay was longer in patients with SAP compared with those with MoAP and MAP (37, 17, and 6 days, respectively; P < 0.0001), as was the likelihood of ICU admission (92%, 26%, 6%; P < 0.0001). Patients with SAP were more likely to have multiorgan failure than single organ failure (59% vs 41%). Finally, SAP course was fatal in 17% (Table 2 ).
IL8 Genotypes
The frequencies of IL8 A/A and T/T homozygotes, and A/T heterozygotes were determined in controls and patients with AP (Table 3 ). There were no significant differences in the HardyWeinberg equilibrium in patients (P = 0.29) or controls (P = 0.66). Overall, the IL8 genotype was found to affect susceptibility to AP. Patients with AP exhibited a significantly higher proportion of the A/A genotype compared with controls (30 vs 23%; OR, 1.42; 95% CI, 1.00-1.99; P = 0.041) ( Table 3) . We found no statistically significant difference in the frequency of the A/A genotype compared with the T-allele between groups when stratified by severity (MAP, 31% vs 69%; MoAP, 29% vs 71%; SAP, 30% vs 70%; P = 0.58; OR, 1.19; 95% CI, 0.68-2.06).
Collectively, this data demonstrate that the A/A genotype enhances susceptibility to AP but does not impact severity of disease.
Impact of BMI
Obesity is an important modifier of the severity of AP. 10 To examine the interaction between BMI and genotype (geneenvironment interactions), we examined the allele frequency as a function of BMI (BMI, ≥30 kg/m 2 vs <30). Overall, 40% of patients were obese (BMI ≥ 30) compared with 30% of controls (P = 0.004). Consistent with published data, 61% of patients with SAP were obese (vs 32% with MAP and 36% with MoAP). Conversely, 38% of obese patients had SAP (Table 4) . The A/A genotype was more common in obese patients compared with obese controls (37% vs 28%), but this trend did not reach significance (P = 0.14). However, we found a higher proportion of obese patients with A/A genotype developed MAP (P = 0.047) ( Table 4 ).
DISCUSSION
Our study demonstrates that the −251 A/A genotype (rs 4072) in the IL8 promoter predicts susceptibility to AP and is less common in severe disease in obese patients. Similar to risk alleles in inflammatory bowel disease, 13 the effect of −251 A/A genotype was only moderate (OR, 1.42). Collectively, these data imply that IL8 may be involved in the pathogenic mechanism of AP; however, as with genetically complex traits, it does not carry all the risk.
The cytokine IL8 also known as neutrophil chemotactic factor, is produced by PRR-expressing cells including immune cells, mucosal epithelial cells (intestinal and airway cells), and endothelial cells. IL8 is typically produced in sparing quantities at baseline but is rapidly upregulated by sentinel cells upon PRR ligand binding.
14 Functionally, IL8 potently induces the migration of immune cells including neutrophils, macrophages, and T-cells. In the context of host immunity, the physiologic role of IL8 is therefore to promote chemotaxis of effector immune cells and mediate pathogen clearance. The −251 A/A SNP is likely a gain-of-function genotype. Macrophages from patients bearing this genotype exhibit enhanced IL8 to PRR stimulation in vitro suggesting that the A/A genotype lowers the threshold for IL8 synthesis. 15 Collectively, the in vivo function of IL8 coupled with the in vitro data on patients with the −251 A/A genotype permit a testable hypothesis for AP susceptibility. Namely, PAMPs and DAMPs exposed by pancreatic inflammation result in enhanced IL8 cytokine release by PRR-expressing cells, culminating in excessive inflammatory cell infiltrates and pro-inflammatory cytokine production. Thus, patients harboring the A/A genotype are more susceptible to AP, whereas its absence permits more rapid homeostasis after injury. This hypothesis is further supported by the results of studies documenting elevated serum IL8 in patients with AP. 16, 17 Most importantly, this putative mechanism is testable in animal models, which could provide insight into disease mechanism, and ultimately, therapeutics. (17) 15 (4) The modern era of genetic analysis has yielded extensive insight into the genetics and mechanism of GI conditions, including inflammatory bowel disease, liver disease, and hereditary and chronic pancreatitis. 13, 18, 19 In contrast, the data in AP are both limited and suffers from considerable variability, precluding uniform interpretations. 20, 21 In this regard, SNPs in IL8 have been assessed in AP in 2 prior publications. 22, 23 In contrast to our findings, there was no association between the −251 A/A genotype and susceptibility in either study, although 1 study did find it affecting severity. 22 However, those studies collectively recruited fewer patients (n = 100 and 91, respectively) than presented here (n = 357).
Thus far, excepting our data, the MYO9B gene has recently been identified as a risk for AP in a large study. MYO9B encodes an actin-based motor heavy chain termed myosin IXB. 24 Myosin IXB protein is involved in regulation of tight junctions. Susceptibility to AP due to MYO9B is therefore presumably a consequence of abnormal intestinal and/or pancreatic epithelial cell permeability. Two genes, MCP1 and TNFα, have been variably associated with AP severity depending on the population under study. 11, 23, 24 Collectively, larger scale studies are likely needed to clarify whether the variability in the data reflects true population heterogeneity or is a consequence of underpowered data sets.
Gene-environment interactions are critically important in the manifestation of genetically complex traits. In contrast to high penetrance alleles, disease expression in complex traits is a consequence of exposure to environmental risk factor(s) in genetically predisposed individual(s). The rise of genome wide association study studies has accelerated the appreciation for gene-environment interactions, because the risk conferred by genetic susceptibility is generally low. 13 We attempted to combine a known environmental risk (obesity) with this SNP and assess whether obesity potentiates the −251 A/A effect. However, we found that both obese patients and controls had a higher proportion of the A/A genotype compared with nonobese counterparts. The lack of significance in the obese group is most likely to be a consequence of the increased incidence of the A/A genotype in obese controls compared with nonobese controls (28% vs 21%).
Acute pancreatitis continues to have a large economic burden. Despite recent advances in clinical management of the complications of AP, significant proportions of patients progress to organ failure with high morbidity and mortality. Genetic studies offer the possibility of identifying pathophysiologic pathways that may be targets of medical therapy. Collectively, our study, which is strengthened by the large number of patients, demonstrates that the −251 A/A allele confers susceptibility to AP. Furthermore, it is consistent with prior publications associating the −251 A/A genotype with inflammatory conditions.
Our data combined with the in vivo biology of IL8 suggest that the moderate susceptibility conferred by the A/A genotype may be mediated by enhanced effector cell infiltration and proinflammatory cytokine production and cumulatively provides the clinical basis to investigate this mechanism in translational studies in humans and murine models. 
(72)
Data expressed as n (%). *P = 0.004; comparisons are between the ratio of obese to nonobese subjects within AP and control (χ 2 test). † P = 0.004; comparisons are between AP and controls. ‡ P = 0.047; comparisons are between AP and controls.
